European Journal of Clinical Pharmacology

, Volume 32, Issue 6, pp 607–610 | Cite as

Disposition of moracizine (ethmozine) in healthy subjects after oral administration of radiolabelled drug

  • D. L. Howrie
  • H. J. PieniaszekJr.
  • R. N. Fogoros
  • R. P. Juhl
  • W. L. Schary
  • C. C. WhitneyJr.
  • L. W. Dittert


Moracizine (ethmozine) is a phenothiazine derivative with demonstrated antiarrhythmic activity. To characterize the pharmacokinetics and material balance relationships in humans, we have given14C-moracizine·HCl as a single oral dose of 500 mg (50 μCi) to six healthy men. Plasma, urine, and faecal samples were collected for 7 days after administration and the concentrations of total radioactivity and intact moracizine were determined by liquid scintillation counting and HPLC, respectively.

Urine and faecal recovery accounted for 95% of the administered radioactivity. Most of this radioactivity was found in the faeces (59%). Only 0.05% of the dose was recovered from urine as intact moracizine.

The Cmax and AUC for moracizine equivalents of total radioactivity were 4- and 18-fold higher, respectively, than the corresponding values for intact moracizine. Additionally, both the disappearance of total radioactivity from plasma and its excretion rate into urine were slower in comparison to intact drug. Terminal t1/2 values calculated from plasma concentration-time data were 85.2 and 3.5 h for total radioactivity and intact moracizine, respectively. However, based on urinary excretion rates, the t1/2 for total radioactivity was shorter (29.3 h) while the t1/2 for intact drug was comparable (2.7 h) to the results obtained from the plasma data. The oral plasma clearance of moracizine was relatively large (2.2l·min−1), suggesting first-pass metabolism. The estimated oral systemic availability of moracizine was 34%.

Key words

moracizine·HCl antiarrhythmic ethmozine radiolabelled pharmacokinetics material balance healthy subjects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Morganroth J, Orth DW, Michelson EL, Dunkman WB, Pearlman AS, Horowitz LN, Josephson ME, Kastor JA (1978) Comparative antiarrhythmic efficacy and tolerance of ethmozin and quinidine. Circulation 57/58 [Suppl. II]: 103Google Scholar
  2. 2.
    Morganroth J, Pearlman AS, Dunkman WB, Horowitz LN, Josephson ME, Michelson EL (1979) Ethmozin: A new antiarrhythmic agent developed in USSR. Efficacy and tolerance. Am Heart J 98: 621–628PubMedCrossRefGoogle Scholar
  3. 3.
    Podrid PJ, Lyakishev A, Lown B, Mazur N (1980) Ethmozin, a new antiarrhythmic drug for suppressing ventricular premature complexes. Circulation 61: 450–457PubMedGoogle Scholar
  4. 4.
    Pratt CM, Yepsen SC, Taylor AA, Mason DT, Miller RR, Quinones MA, Lewis RA (1983) Ethmozine suppression of single and repetitive ventricular premature depolarizations during therapy: Documentation of efficacy and long-term safety. Am Heart J 106: 85–91PubMedCrossRefGoogle Scholar
  5. 5.
    Pratt CM, Young JB, Francis MJ, Taylor AA, Norton HJ, English L, Mann DE, Kopelen H, Quinones MA, Roberts R (1984) Comparative effect of disopyramide and ethmozine in suppressing complex ventricular arrhythmias by use of a double-blind, placebo-controlled, longitudinal crossover design. Circulation 69: 288–297PubMedGoogle Scholar
  6. 6.
    Piotrovskii VK, Merkulova IN, Romina NN, Metelitsa VI (1982) Pharmacokinetics of ethmozine after a single intravenous injection [English translation]. Kardiologiya 22: 75–80PubMedGoogle Scholar
  7. 7.
    Piotrovskii VK, Romina NN, Merkulova IN, Kurbanov, RD, Metelitsa VI, Mazar NA (1983) Bioavailability of ethmozine with oral administration [English translation]. Khim Farm Zh 221: 912–916Google Scholar
  8. 8.
    MacFarland RT, Moeller VR, Pieniaszek HJ Jr, Whitney CC, Jr, Marcus FI (1985) Assessment of the potential pharmacokinetic interaction between digoxin and ethmozine. J Clin Pharmacol 25: 138–143PubMedGoogle Scholar
  9. 9.
    Biollaz JB, Shaheen O, Wood AJJ (1985) Cimetidine inhibition of ethmozine metabolism. Clin Pharmacol Ther 37: 665–668PubMedCrossRefGoogle Scholar
  10. 10.
    Vikhlyaev YI, Zherdev VP, Gritsenko AN, Ermakova ZI (1977) Features of ethmozine metabolism [English translation]. Farmakol Toksikol 40: 19–22Google Scholar
  11. 11.
    Whitney CC, Weinstein SH, Gaylord JC (1981) High-performance liquid chromatographic determination of ethmozin in plasma. J Pharm Sci 70: 462–463PubMedGoogle Scholar
  12. 12.
    Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New YorkGoogle Scholar
  13. 13.
    Lam FC, Hung CT, Perrier DG (1985) Estimation of variance for harmonic mean half-lives. J Pharm Sci 72: 229–231Google Scholar
  14. 14.
    Schaaf LJ, Lam FC, Perrier DG (1986) Comparison of harmonic mean versus arithmetic mean clearance values. J Pharm Sci 75: 427–429PubMedGoogle Scholar
  15. 15.
    Greenway CV, Stark RD (1971) Hepatic vascular bed. Physiol Rev 51: 23–65PubMedGoogle Scholar
  16. 16.
    Dubois D, Dubois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17: 863–871Google Scholar
  17. 17.
    Rowland M, Tozer TN (1980) Clinical pharmacokinetics — concepts and applications, Lea and Febiger, PhiladelphiaGoogle Scholar
  18. 18.
    Hollister LE (1983) Antipsychotic drugs. In: Clinical pharmacology of psychotherapeutic drugs, 2nd edn. Churchill Livingstone, New YorkGoogle Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • D. L. Howrie
    • 1
  • H. J. PieniaszekJr.
    • 1
  • R. N. Fogoros
    • 2
  • R. P. Juhl
    • 1
  • W. L. Schary
    • 4
  • C. C. WhitneyJr.
    • 3
  • L. W. Dittert
    • 1
  1. 1.School of PharmacyUniversity of PittsburghPittsburghUSA
  2. 2.School of MedicineUniversity of PittsburghPittsburghUSA
  3. 3.DuPont Pharmaceuticals Medical Products Department Drug Metabolism SectionStine-Haskell Research CenterNewarkUSA
  4. 4.Medical Research SectionDuPont PharmaceuticalsWilmingtonUSA

Personalised recommendations